456 related articles for article (PubMed ID: 30993437)
21. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.
Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C
Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759
[TBL] [Abstract][Full Text] [Related]
22. Value of discrepancy of the central scar-like structure between dynamic CT and gadoxetate disodium-enhanced MRI in differentiation of focal nodular hyperplasia and hepatocellular adenoma.
Park HJ; Byun JH; Kang JH; Kang HJ; Yu E; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
Eur J Radiol; 2021 Jun; 139():109730. PubMed ID: 33930719
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium.
Bieze M; van den Esschert JW; Nio CY; Verheij J; Reitsma JB; Terpstra V; van Gulik TM; Phoa SS
AJR Am J Roentgenol; 2012 Jul; 199(1):26-34. PubMed ID: 22733890
[TBL] [Abstract][Full Text] [Related]
24. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.
Reizine E; Ronot M; Pigneur F; Purcell Y; Mulé S; Dioguardi Burgio M; Calderaro J; Amaddeo G; Laurent A; Vilgrain V; Luciani A
Eur Radiol; 2019 Jul; 29(7):3791-3801. PubMed ID: 30937584
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
26. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.
Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C
Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633
[TBL] [Abstract][Full Text] [Related]
27. Gadobenate-dimeglumine-enhanced magnetic resonance imaging for hepatic lesions in children.
Chavhan GB; Mann E; Kamath BM; Babyn PS
Pediatr Radiol; 2014 Oct; 44(10):1266-74. PubMed ID: 24771094
[TBL] [Abstract][Full Text] [Related]
28. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
[TBL] [Abstract][Full Text] [Related]
29. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules.
Kim JW; Lee CH; Kim SB; Park BN; Park YS; Lee J; Park CM
J Magn Reson Imaging; 2017 Jun; 45(6):1599-1608. PubMed ID: 27726242
[TBL] [Abstract][Full Text] [Related]
30. Performance of Contrast-Enhanced Sonography Versus MRI With a Liver-Specific Contrast Agent for Diagnosis of Hepatocellular Adenoma and Focal Nodular Hyperplasia.
Bröker MEE; Taimr P; de Vries M; Braun LMM; de Man RA; Ijzermans JNM; Dwarkasing RS
AJR Am J Roentgenol; 2020 Jan; 214(1):81-89. PubMed ID: 31573852
[No Abstract] [Full Text] [Related]
31. Quantification of liver fat content in liver and primary liver lesions using triple-echo-gradient-echo MRI.
Nougaret S; Monsonis B; Molinari N; Riviere B; Piron L; Kassam Z; Cassinotto C; Guiu B
Eur Radiol; 2020 Sep; 30(9):4752-4761. PubMed ID: 32318848
[TBL] [Abstract][Full Text] [Related]
32. Efficacy comparison of multi-phase CT and hepatotropic contrast-enhanced MRI in the differential diagnosis of focal nodular hyperplasia: a prospective cohort study.
Nowicki TK; Markiet K; Izycka-Swieszewska E; Dziadziuszko K; Studniarek M; Szurowska E
BMC Gastroenterol; 2018 Jan; 18(1):10. PubMed ID: 29334905
[TBL] [Abstract][Full Text] [Related]
33. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging.
Marin D; Iannaccone R; Laghi A; Catalano C; Murakami T; Hori M; Kim T; Passariello R
J Magn Reson Imaging; 2007 Apr; 25(4):775-82. PubMed ID: 17348002
[TBL] [Abstract][Full Text] [Related]
34. Liver biopsy for diagnosis of presumed benign hepatocellular lesions lacking magnetic resonance imaging diagnostic features of focal nodular hyperplasia.
Sannier A; Cazejust J; Lequoy M; Cervera P; Scatton O; Rosmorduc O; Wendum D
Liver Int; 2016 Nov; 36(11):1668-1676. PubMed ID: 26969817
[TBL] [Abstract][Full Text] [Related]
35. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
36. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
[TBL] [Abstract][Full Text] [Related]
37. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors.
Zarghampour M; Fouladi DF; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Khoshpouri P; Shao N; Pan L; Grimm R; Kamel IR
J Magn Reson Imaging; 2018 Oct; 48(4):1080-1090. PubMed ID: 29630756
[TBL] [Abstract][Full Text] [Related]
38. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
Grazioli L; Morana G; Caudana R; Benetti A; Portolani N; Talamini G; Colombari R; Pirovano G; Kirchin MA; Spinazzi A
Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
[TBL] [Abstract][Full Text] [Related]
39. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.
Scharitzer M; Schima W; Schober E; Reimer P; Helmberger TK; Holzknecht N; Stadler A; Ba-Ssalamah A; Weber M; Wrba F
J Comput Assist Tomogr; 2005; 29(2):181-90. PubMed ID: 15772534
[TBL] [Abstract][Full Text] [Related]
40. Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions.
Fu GL; Du Y; Zee CS; Yang HF; Li Y; Duan RG; Zeng NL; Xiao DM
J Comput Assist Tomogr; 2012; 36(1):14-9. PubMed ID: 22261765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
